Tradegate
06.02.26 | 20:48
23,960 Euro
+0,50 % +0,120
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,660 | 24,020 | 13:05 | |
| 23,660 | 24,000 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | Medincell - UZEDY: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) | 278 | Business Wire | OLANZAPINE LAI: EU Submission Expected in Q2 2026
Regulatory News:
Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication... ► Artikel lesen | |
| 20.01. | Medincell: Half-year Liquidity Contract Statement | 230 | Business Wire | Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025:... ► Artikel lesen | |
| 12.01. | Medincell: Publication of the 2026 Financial Calendar | 293 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Event Date
Annual results 2025-2026
(April 2025-March 2026)
Tuesday, June 16, 2026
General Meeting
Thursday... ► Artikel lesen | |
| 09.12.25 | Medincell: Starkes Umsatzwachstum, doch anhaltende Verluste belasten den Aktienkurs | 4 | Investing.com Deutsch | ||
| 09.12.25 | Medincell Publishes its Consolidated Half-Year Financial Results | 407 | Business Wire | (April 1st, 2025 September30, 2025)
Regulatory News:
Christophe Douat, CEO of Medincell (Paris:MEDCL)"We are pleased with the company's growth and momentum. We have entered the most transformative... ► Artikel lesen | |
| 09.12.25 | Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults | 454 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad... ► Artikel lesen | |
| 01.12.25 | Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025 | 364 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)
Meeting in French, 6:00... ► Artikel lesen | |
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 27.11.25 | Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference | 462 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will... ► Artikel lesen | |
| 24.11.25 | Medincell Awarded New Grant to Fight Malaria | 335 | Business Wire | Medincell to receive a $3 million grant from the Gates Foundation to advance mdc-STM malaria program. mdc-STM program is an investigational, three-month, subcutaneous injectable formulation of... ► Artikel lesen | |
| 13.11.25 | Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025) | 371 | Business Wire | Regulatory News:
Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the... ► Artikel lesen | |
| 11.11.25 | Medincell Promotes Grace Kim Chief Strategy Officer U.S. Finance | 1 | Contract Pharma | ||
| 11.11.25 | Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth | 382 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL), a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy... ► Artikel lesen | |
| 10.11.25 | Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark | 364 | Business Wire | Medincell has been selected for inclusion in the Morgan Stanley Capital International (MSCI) World Small Cap Index, which encompasses the most liquid and high-performing small-cap companies across... ► Artikel lesen | |
| 06.11.25 | Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York) | 424 | Business Wire | Regulatory News:
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, and Dr Richard Malamut, Chief Medical Officer, will speak on Medincell's (Paris:MEDCL) value proposition, including recent... ► Artikel lesen | |
| 05.11.25 | Medincell: UZEDY Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025 | 517 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About Olanzapine Long-Acting Injectable (TEV-749 mdc-TJK)
1-Month subcutaneous... ► Artikel lesen | |
| 22.10.25 | Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York) | 369 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will speak on Medincell's value proposition, including recent developments and meet with investors... ► Artikel lesen | |
| 13.10.25 | FDA approves Teva and Medincell's bipolar I disorder treatment | 27 | Pharmaceutical Technology | ||
| 10.10.25 | Medincell: FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder | 543 | Business Wire | FDA approves UZEDY (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar... ► Artikel lesen | |
| 23.09.25 | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 625 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| 22.09.25 | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 461 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| PAION | 0,200 | +8,11 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| AMGEN | 325,15 | +0,06 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| STRYKER | 302,10 | -0,33 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| BIOGEN | 164,25 | +3,79 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| BIOFRONTERA | 2,420 | -1,22 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,910 | 0,00 % | HEIDELBERG PHARMA AG zeigt klare Stärke im Trend | ||
| ILLUMINA | 101,04 | -0,18 % | Illumina-Aktie -10%: Kann man hier günstig einsteigen? | Mit einem Kursverlust von -10% war die Illumina-Aktie am Freitag der große Verlierer im S&P 500. Der Hersteller von Gensequenzierungsmaschinen setzte damit seinen Abwärtstrend der letzten Tage fort.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MEDINCELL SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 23,960 Euro und damit +0,50 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.